Table 1.

Clinical characteristics of the analysed cohort (26 patients).

Patient ID	Gender	Tumour-free tissue*	Tumour tissue*	Cancer diagnosis	Age (years)	BMI	PY	GOLD stage
ID2	Male	+	+	SCC	71	35	60–70	1
ID4	Male	+	+	SCC	66	25	>100	1
ID6	Male	+	+	SCC	70	28	50	1
ID11	Male	+	−	ADC	48	NA	NA	NA
ID12	Male	+	+	SCC	70	21	50	2
ID15	Male	+	−	SCC	45	40	70	2
ID17	Male	+	−	SCC	68	NA	NA	2
ID18	Female	+	+	SCC	47	32	50	No COPD#
ID19	Female	+	+	other	54	28	35	1
ID22	Male	+	+	SCC	57	25	25	1
ID24	Male	+	+	SDC	55	26	40	No COPD#
ID29	Male	+	+	SCC	59	29	40	No COPD#
ID30	Male	−	+	ADC	52	27	30	3
ID31	Male	−	+	SCC	68	33	100–150	2
ID32	Male	−	+	ADC	45	23	30	1
ID39	Male	+	+	SCC	60	25	40	2
ID43	Male	+	+	other	60	23	30	1
ID50	Male	+	+	SCC	63	25	47	1
ID52	Female	+	−	other	44	27	10	Restriction with pneumonia
ID53	Male	+	+	ADC	48	29	30	No COPD#
ID61	Male	+	+	ADC	70	18	60	2
ID64	Female	+	+	ADC	51	27	35	1
ID66	Male	+	+	ADC	62	28	45	1
ID67	Female	+	+	ADC	52	30	50	2
ID71	Female	−	+	ADC	57	21	30	1
ID72	Male	−	+	ADC	62	34	40	2

NA, not available; BMI, body mass index; PY, pack-years; GOLD, Global Initiative for Chronic Obstructive Lung Disease; COPD, chronic obstructive pulmonary disease; ADC, adenocarcinoma; SCC, squamous cell carcinoma; other, tumour diagnosis was either large-cell carcinoma (ID19), sarcomatoid large cell carcinoma (ID43) and carcinoid tumour (ID52).

^*Tissue sample availability for the analysis is indicated; for all lipidomics analysis, 14.4 mg wet-weight was extracted.

^#For the diagnosis ‘No COPD’, the GOLD stage was set to zero for all data analysis strategies.